The potential role of soyfoods in weight and adiposity reduction: An evidence-based review
Department of Nutrition Sciences, University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA. Obesity Reviews
(Impact Factor: 8).
06/2008; 9(3):219-35. DOI: 10.1111/j.1467-789X.2007.00390.x
Evidence concerning the relationship between soyfoods and weight loss was reviewed. Detailed searches of PubMed and Web of Science were performed to identify and evaluate evidence for or against four propositions related to soyfoods and weight loss (Data from in vitro, animal, epidemiologic, and clinical studies were evaluated and summarized). (1) Certain soyfoods will improve weight and/or fat loss when fed at isolcaloric levels (similar calories given across experimental conditions, but not necessarily at a level to maintain current body weight); generally supportive evidence in animal studies, but there is no compelling support in human studies. (2) Certain soyfoods will improve weight and fat loss when included as part of a diet by affecting caloric intake; limited supportive evidence in animal and human studies. (3) Certain soyfoods will prevent/improve risk factors related to glucoregulatory function and cardiovascular health during weight loss; some evidence supporting this proposition, but additional evidence is needed before conclusions can be made. (4) Certain soyfoods will minimize the loss of bone mass during weight loss; no data available pertinent to this proposition. Limitations in existing data make it difficult to reach conclusions regarding these four propositions. Overall, the current data suggest that soyfoods are as good as other protein sources for promoting weight loss and there is a suggestive body of evidence that soyfoods may confer additional benefits, but results must be carefully interpreted and additional evidence is needed before making firm conclusions concerning soyfoods and weight loss.
Available from: Robin Mcgregor
- "Remarkably the increase in cholesterol intake evident in the EGML, GCE and placebo groups over 10 weeks was also reflected in plasma total cholesterol levels within all groups. In agreement with past studies the present study provided no evidence that EGML or GCE supplementation can modify calorie intake in overweight individuals consuming their habitual diet . "
[Show abstract] [Hide abstract]
ABSTRACT: Natural food supplements with high flavonoid content are often claimed to promote weight-loss and lower plasma cholesterol in animal studies, but human studies have been more equivocal. The aim of this study was firstly to determine the effectiveness of natural food supplements containing Glycine max leaves extract (EGML) or Garcinia cambogia extract (GCE) to promote weight-loss and lower plasma cholesterol. Secondly to examine whether these supplements have any beneficial effect on lipid, adipocytokine or antioxidant profiles.
Eighty-six overweight subjects (Male:Female = 46:40, age: 20~50 yr, BMI > 23 < 29) were randomly assigned to three groups and administered tablets containing EGML (2 g/day), GCE (2 g/day) or placebo (starch, 2 g/day) for 10 weeks. At baseline and after 10 weeks, body composition, plasma cholesterol and diet were assessed. Blood analysis was also conducted to examine plasma lipoproteins, triglycerides, adipocytokines and antioxidants.
EGML and GCE supplementation failed to promote weight-loss or any clinically significant change in %body fat. The EGML group had lower total cholesterol after 10 weeks compared to the placebo group (p < 0.05). EGML and GCE had no effect on triglycerides, non-HDL-C, adipocytokines or antioxidants when compared to placebo supplementation. However, HDL-C was higher in the EGML group (p < 0.001) after 10 weeks compared to the placebo group.
Ten weeks of EGML or GCE supplementation did not promote weight-loss or lower total cholesterol in overweight individuals consuming their habitual diet. Although, EGML did increase plasma HDL-C levels which is associated with a lower risk of atherosclerosis.
Nutrition Journal 09/2011; 10(1):94. DOI:10.1186/1475-2891-10-94 · 2.60 Impact Factor
Available from: Takashi Arao
- "from food group A as action plan targets. Thus, subjects could select such food groups with the expectation of an equal effect on the target problem, as all items in food A group are effective in ameliorating impaired glucose tolerance, hypertension, and hyperlipidemia (Japan Association of Diabetes Care and Education, 2003; de Castro et al., 2006; Cope et al., 2008). However, items in food group B had different effects on various disorders, possibly requiring the selection of greater numbers of food items by subjects with multiple risk factors. "
[Show abstract] [Hide abstract]
ABSTRACT: An effective program for preventing metabolic diseases through lifestyle modification is urgently needed. We investigated the effects of the Life Style Modification Program for Physical Activity and Nutrition program (LiSM10!) on metabolic parameters in middle-aged male Japanese white-collar workers.
One hundred and one male office workers, 30 to 59 years of age, with metabolic syndrome risk factors, were randomly allocated into no-treatment control (n=49) and LiSM intervention (n=52) groups. The LiSM group attended individualized assessment and collaborative goal setting sessions based on food group intake and physical activity, followed by two individual counseling sessions with a registered dietitian and physical trainer, and received monthly website advice during the 4-month period from December 2006 to May 2007, in Tokyo, Japan. They were encouraged to enter current targeted food intakes and pedometer data on self-monitoring websites during the entire study period.
Habitual food group intakes changed significantly in the LiSM group, showing improvements in 14 anthropometric and biochemical parameters contributing to inter-group differences in body weight, body mass index, fasting plasma glucose, insulin and homeostasis model assessment of insulin resistance changes (p<0.01).
The LiSM10! program effectively improved insulin resistance-related metabolic parameters in middle-aged male white-collar workers.
Preventive Medicine 07/2010; 51(1):11-7. DOI:10.1016/j.ypmed.2010.04.008 · 3.09 Impact Factor
- "Scientific evidence concerning the role of soy protein and body weight reduction is increasing (Cope et al., 2007; Velasquez & Bhathena, 2007; Xiao, 2008). However, despite intense studies in this area the active protein component responsible for the effects of soy protein on weight and adiposity reduction is still unclear. "
[Show abstract] [Hide abstract]
ABSTRACT: The objective was to assess the effect of protein hydrolysates of β-conglycinin enriched soybean on fatty acid synthase (FAS) activity and adipogenic response of human adipocytes in vitro. The results showed that genotypic changes in soybean protein subunits produced peptide profiles that led to inhibition of FAS and lipid accumulation in vitro. FAS inhibitory potency (IC50) of soy protein hydrolysates (SPH) ranged from 50 to 175 μM, while lipid inhibition from 15.6% to 45.9%. Protein hydrolysate C2H from a soybean containing the highest total β-conglycinin (46.9%) showed the most potent inhibitory effect on in vitro adipogenesis (46%) and FAS (IC50 = 50 μM). C2H was composed of dominant peptides from fragments f(85–112) and f(131–132) of β-conglycinin α subunit. Smaller peptides identified as fragments f(330–342) and f(329–342) of α′ subunit were also found. In conclusion, soybean genotypes enriched in β-conglycinin α and α′ subunits are suitable sources of active peptides that inhibit FAS activity and lipid accumulation.
Food Chemistry 04/2010; 119(4):1571-1577. DOI:10.1016/j.foodchem.2009.09.044 · 3.39 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.